Woomera Therapeutics

Woomera TherapeuticsWoomera TherapeuticsWoomera Therapeutics
  • Sign In
  • Create Account

  • Orders
  • My Account
  • Signed in as:

  • filler@godaddy.com


  • Orders
  • My Account
  • Sign out

  • Home
  • Product list
  • Contact Us
  • Shop
  • More
    • Home
    • Product list
    • Contact Us
    • Shop

Woomera Therapeutics

Woomera TherapeuticsWoomera TherapeuticsWoomera Therapeutics

Signed in as:

filler@godaddy.com

  • Home
  • Product list
  • Contact Us
  • Shop

Account


  • Orders
  • My Account
  • Sign out


  • Sign In
  • Orders
  • My Account

Rabbit Oxytocin-Human Neurophysin Antibodies

Product Name: Rabbit Oxytocin-Human Neurophysin Antibodies (OT-HNP, HNP1) Antibodies (ARC, PTR, PL)

These are antibody preparations generated in rabbit by Dr. William North Professor of Physiology and Neurobiology of Dartmouth Medical School (now Geisel School of Medicine at Dartmouth College) using vasopressin associated human neurophysin protein purified by preparative electrophoresis and preparative isofocusing as antigen. 


Specificity:                    1-5% cross-reactivity with Human Neurophysins 3 (Vasopressin-Associated Human Neurophysin, VP-HNP). 


Tested Applications:  IHC-formaldehyde fixed tissues, Flow cytometry , RIA, ELISA, Western 

Properties 


Form Liquid 


Storage Instructions: Shipped at 4 o C. Store at 4 o C short term (1-2 weeks). Upon delivery aliquot and store at -20 o C or -80 o C. Avoid freeze/Thaw cycling. 


Storage buffer:           Preservative none. Stable if stored as 1:100 dilutions in PBS containing  1.25 mg/ml of BSA at -20 o C. 


Constituents:              Whole serum 


Purity:                           Whole Antiserum 


Clonality:                    Polyclonal 


Isotype:                      IgG, Behaves chromatographically like mouse IgG2B  


Research Areas:      Neuroscience, Endocrinology, Neuropeptides, Hormones, Oncology, Neuroendocrinology, Measurement of Vasopressin Release.  


----------------------------------------------------------------------------------


Woomera Therapeutics Inc. guarantees use of ARC, PTR, and PL in each of the tested applications: 

The application information recommends certain starting dilutions; however, optimal dilutions/concentrations should be determined by the end user. 


Application 


IHC:                           1:5000-10,000, Use at an assay dependent concentration 


RIA:                            1/10,000-1/50,000, Sensitivity to 5-10 pg, range 10-320 pg; 50% displacement at ~50 pg; ; ~1-5% OT-HNP cross-reaction.  


ELISA:                        1/10,000


Flow Cytometry:    1/1000 


Western:                  1/1000 


Reference 


North, W.G., LaRochelle, F.T., Jr., Melton, J., and Mills, R.C. Isolation and partial characterization of two human neurophysins: Their use in the development of specific radioimmunoassays. J. Clin. Endocrinol. Metab. 51:884-891, 1980. 

North, W.G., Maurer, L.H., Valtin, H., and O'Donnell, J.F. Human neurophysins as potential tumor markers for small cell carcinoma of the lung: Application of specific radioimmunoassays. J. Clin. Endocrinol. Metab. 51:892-896, 1980.  

North, W.G., Ware, J., Chahinian, A.P., Perry, M., O'Donnell, J., and Maurer, L.H. Clinical evaluation of the neurophysins as tumor markers in small cell lung cancer. Recent Results in Cancer Res. 99:187-193, 1985.  

North, W.G., Ware, J., Maurer, L.H., Chahinian, A.P., and Perry, M. Neurophysins as tumor markers for small cell carcinoma of the lung: A cancer and leukemia group B evaluation. Cancer 62:1343-1347, 1988.  

North, W.G., Hirsh, V., Lisbona, R., Schulz, J., and Cooper, B. Imaging of small cell carcinoma using 131 I-labelled antibodies to vasopressin associated human neurophysin (VP-HNP). Nuclear Medicine Communications 10:643-651, 1989. 

North, W.G., Harbaugh, R., and Reeder, T. An evaluation of human neurophysin production in Alzheimer's disease: Preliminary observations. Neurobiol. Aging 13(2):261-265, 1992. 

North, W.G. Neuropeptide production by small-cell carcinoma: Vasopressin and oxytocin as plasma markers of disease. J. Clin. Endocrin. Metab. 73:1316-1320, 1991. 

Friedmann, A.S., Memoli, V.A., Yu, X-M., and North, W.G. Biosynthesis of vasopressin by gastrointestinal cells of Brattleboro and Long-Evans rats. Peptides 14:607-612, 1993.  

Friedmann, A.S., Memoli, V.A., and North, W.G. Vasopressin and oxytocin production by non- neuroendocrine lung carcinomas: an apparent low incidence of gene expression. Cancer Letters 75:79-85, 1993.  

Friedmann, A.S., Malott, K.A., Memoli, V.A., Pai, S.I., Yu, X.-M., and North, W.G. Products of vasopressin gene expression in small-cell carcinoma of the lung. Br. J. Cancer 69:260-263, 1994. 

North, W.G., Pai, S., Friedmann, A., Yu, X., Fay, M., and Memoli, V. Vasopressin gene related products are markers of human breast cancer. Breast Cancer Research and Treatment 34:229- 235, 1995.  

Friedmann, A.S., Fay, M.J., Memoli, V.A. and North, W.G. Factors regulating the production of vasopressin-associated human neurophysin by small-cell carcinoma of the lung: Evaluation by computer-enhanced quantitative immunocytochemistry. Neuropeptides 28:183-189, 1995. 

Fay, M.J., Mathew, R.S., Donnelly, E.M., Memoli, V.A., and North, W.G. Immunohistochemical evaluation of vasopressin gene expression in fibrocystic breast disease. Endocrine Pathology, In Press, 2000. 

North,W.G., Wells,W., Fay, M.J., Mathew, R.J., Donnelly, E.M., and Memoli, V.A. Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS). Endocrin. Pathology, 14, 257-262, 2003.  


Product codes: ARC, PTR, PL


Copyright © 2025 Woomera Therapeutics - All Rights Reserved.

  • Privacy Policy
  • Terms and Conditions

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept